Zosuquidar

DRUG2 trials

Sponsors

Kanisa Pharmaceuticals

Conditions

Leukemia, Myeloid

Phase 1

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

CompletedNCT00129168

Kanisa PharmaceuticalsLeukemia, Myeloid

Start: 2005-08-31End: 2008-03-31Target: 100Updated: 2008-04-01

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

CompletedNCT00233909

Kanisa PharmaceuticalsLeukemia, Myeloid

Start: 2005-10-31End: 2008-03-31Target: 55Updated: 2008-04-01

Related Papers

Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype.

2024-02-264 citations

A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.

2023-08-214 citations